NZ732628A - Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof - Google Patents

Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof

Info

Publication number
NZ732628A
NZ732628A NZ732628A NZ73262815A NZ732628A NZ 732628 A NZ732628 A NZ 732628A NZ 732628 A NZ732628 A NZ 732628A NZ 73262815 A NZ73262815 A NZ 73262815A NZ 732628 A NZ732628 A NZ 732628A
Authority
NZ
New Zealand
Prior art keywords
binding specificity
making
methods
bispecific tetravalent
family members
Prior art date
Application number
NZ732628A
Other languages
English (en)
Inventor
Zeren Gao
phil Tan
Brian Kovacevich
Blair Renshaw
Jeffrey Adamo
Nga Sze Amanda Mak
Shi Zhuo
Lan Chen
Zhu Yi
Original Assignee
Systimmune Inc
Sichuan Baili Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc, Sichuan Baili Pharmaceutical Co Ltd filed Critical Systimmune Inc
Publication of NZ732628A publication Critical patent/NZ732628A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ732628A 2014-12-22 2015-12-19 Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof NZ732628A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095348P 2014-12-22 2014-12-22
PCT/US2015/066951 WO2016106157A1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof

Publications (1)

Publication Number Publication Date
NZ732628A true NZ732628A (en) 2019-01-25

Family

ID=56151464

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ732628A NZ732628A (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof

Country Status (22)

Country Link
US (2) US10717783B2 (cg-RX-API-DMAC7.html)
EP (3) EP3237006B1 (cg-RX-API-DMAC7.html)
JP (2) JP6947639B2 (cg-RX-API-DMAC7.html)
KR (4) KR102548827B1 (cg-RX-API-DMAC7.html)
CN (11) CN106659779B (cg-RX-API-DMAC7.html)
AU (1) AU2015369831B2 (cg-RX-API-DMAC7.html)
CA (2) CA2969867C (cg-RX-API-DMAC7.html)
DK (1) DK3237005T3 (cg-RX-API-DMAC7.html)
ES (2) ES2962675T3 (cg-RX-API-DMAC7.html)
FI (1) FI3237005T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241502T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069256T2 (cg-RX-API-DMAC7.html)
IL (3) IL305193A (cg-RX-API-DMAC7.html)
LT (1) LT3237005T (cg-RX-API-DMAC7.html)
NZ (1) NZ732628A (cg-RX-API-DMAC7.html)
PL (1) PL3237005T3 (cg-RX-API-DMAC7.html)
PT (1) PT3237005T (cg-RX-API-DMAC7.html)
RS (1) RS66070B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201704741PA (cg-RX-API-DMAC7.html)
SI (1) SI3237005T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400477T1 (cg-RX-API-DMAC7.html)
WO (2) WO2016106157A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
IL305193A (en) * 2014-12-22 2023-10-01 Systimmune Inc Bispecific tetravalent antibodies and methods for their preparation and use
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CN108948195B (zh) * 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
EP3645742A4 (en) * 2017-06-25 2021-07-14 Systimmune, Inc. Anti-ror1 antibodies and methods of making and using thereof
CA3069238A1 (en) * 2017-11-02 2019-05-09 Systimmune, Inc. Bispecific antibodies and methods of making and using thereof
WO2019137548A1 (en) * 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against tigit
CN108220244A (zh) * 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
CN107974461A (zh) * 2018-01-18 2018-05-01 东北农业大学 一种高效表达anti-hEGFR基因的真核表达载体构建方法
CN112119097B (zh) * 2018-04-13 2021-10-15 艾菲默德有限责任公司 自然杀伤细胞接合抗体融合构建体
CN118852450A (zh) * 2018-05-16 2024-10-29 嘉立医疗科技(广州)有限公司 双特异性抗体组合物及其使用方法
EP3833690B1 (en) * 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Recombinant bifunctional protein targeting cd47 and her2
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
WO2020061376A2 (en) * 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
CN119798453A (zh) * 2018-11-13 2025-04-11 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
EP4004053A4 (en) * 2019-07-26 2023-10-18 ABL Bio, Inc. BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND ITS USE
EP4010371A1 (en) 2019-08-08 2022-06-15 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
EP4181950A4 (en) * 2020-02-19 2024-07-17 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN111548424A (zh) * 2020-06-05 2020-08-18 上海科弈药业科技有限公司 一种靶向egfr与cd47的多功能融合蛋白及其应用
MX2023003303A (es) * 2020-09-21 2023-05-09 Systimmune Inc Anticuerpo biespecifico de especificidad mejorada (seba).
US20240309099A1 (en) * 2021-08-25 2024-09-19 Systimmune, Inc. Bispecific tetravalent antibody targeting egfr and her3
EP4405396A2 (en) * 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN118302192A (zh) * 2021-10-03 2024-07-05 西雅图免疫公司 治疗癌症的方法及其药物组合物
MX2024005831A (es) * 2021-11-15 2024-07-09 Systimmune Inc Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo.
WO2023241480A1 (zh) * 2022-06-13 2023-12-21 三优生物医药(上海)有限公司 抗pd-l1、vegf和egfr三特异性抗体及其应用
KR20250057870A (ko) * 2022-08-31 2025-04-29 시스트이뮨, 인코포레이티드 Egfr을 표적화하는 이중에피토프 4가 항체
CN116063564A (zh) * 2022-10-08 2023-05-05 盛禾(中国)生物制药有限公司 一种纯化融合蛋白的方法
CN118829655A (zh) * 2023-02-15 2024-10-22 浙江时迈药业有限公司 Egfr和lag3双靶向的双特异性抗体及其用途
TW202502823A (zh) * 2023-07-07 2025-01-16 大陸商四川科倫博泰生物醫藥股份有限公司 Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途
WO2025026282A1 (en) * 2023-07-29 2025-02-06 Shanghai Kaijin Biotechnology, Ltd Modified type e multi-specific antibodies
WO2025117871A1 (en) * 2023-11-29 2025-06-05 Systimmune, Inc. Bispecific tetravalent antibody targeting her2 and her3
WO2025140662A1 (en) * 2023-12-29 2025-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/her3 antibodies and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200753B (en) 1986-12-23 1991-01-23 Brookes & Gatehouse Speed measurement device
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP2048154B2 (en) * 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
MX2008015852A (es) * 2006-06-14 2009-02-23 Imclone Systems Inc Formulaciones liofilizadas de anticuerpos anti-egfr.
AU2007353412A1 (en) * 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
NZ594665A (en) * 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
CN102369215B (zh) * 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
PE20120550A1 (es) * 2009-04-07 2012-05-21 Roche Glycart Ag ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
NZ598929A (en) * 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US10208128B2 (en) * 2009-11-04 2019-02-19 Affibody Ab HER3 binding polypeptides
JP2014504850A (ja) * 2010-09-30 2014-02-27 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
CA2817448C (en) * 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
JP6177231B2 (ja) * 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
ES2667568T3 (es) * 2011-04-25 2018-05-11 Daiichi Sankyo Company, Limited Anticuerpo anti-B7-H3
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250247B (zh) * 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
US8961971B2 (en) * 2011-12-22 2015-02-24 Development Center For Biotechnology Bispecific T-cell activator antibody
RU2014136886A (ru) * 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
CA2878640C (en) * 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
HUE041499T2 (hu) * 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
CN103333179B (zh) * 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
US9388243B2 (en) * 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
IL305193A (en) 2014-12-22 2023-10-01 Systimmune Inc Bispecific tetravalent antibodies and methods for their preparation and use

Also Published As

Publication number Publication date
AU2015369831A1 (en) 2017-06-29
CN113512123B (zh) 2024-10-25
CN117467017A (zh) 2024-01-30
CN107206074B (zh) 2023-12-01
JP6947639B2 (ja) 2021-10-13
SI3237005T1 (sl) 2025-02-28
EP3237005A1 (en) 2017-11-01
IL286835B2 (en) 2024-03-01
IL286835A (en) 2021-10-31
US10919977B2 (en) 2021-02-16
EP3237005A4 (en) 2018-05-23
KR20250094744A (ko) 2025-06-25
IL252811B (en) 2021-10-31
PL3237005T3 (pl) 2025-01-27
CN113512121B (zh) 2024-10-25
CN113105552B (zh) 2024-09-20
JP2018509175A (ja) 2018-04-05
CN106659779A (zh) 2017-05-10
CN107206074A (zh) 2017-09-26
SMT202400477T1 (it) 2025-01-14
LT3237005T (lt) 2024-11-11
JP2021119149A (ja) 2021-08-12
SG11201704741PA (en) 2017-07-28
JP7335290B2 (ja) 2023-08-29
DK3237005T3 (en) 2024-11-18
CA3138083A1 (en) 2016-06-30
AU2015369831B2 (en) 2019-07-11
KR20230149328A (ko) 2023-10-26
EP3237006A4 (en) 2018-05-30
KR20230104988A (ko) 2023-07-11
CN113105553A (zh) 2021-07-13
CN113150165A (zh) 2021-07-23
EP4491195A2 (en) 2025-01-15
CN113105553B (zh) 2024-09-10
KR102548827B1 (ko) 2023-06-30
EP3237005B1 (en) 2024-09-18
IL252811A0 (en) 2017-08-31
EP3237006A1 (en) 2017-11-01
US10717783B2 (en) 2020-07-21
CN113512123A (zh) 2021-10-19
CN113512122A (zh) 2021-10-19
CA2969867A1 (en) 2016-06-30
PT3237005T (pt) 2024-11-18
HUE069256T2 (hu) 2025-02-28
WO2016106157A1 (en) 2016-06-30
IL286835B1 (en) 2023-11-01
CA2969867C (en) 2022-01-25
EP3237006B1 (en) 2023-08-16
KR20170091162A (ko) 2017-08-08
KR102823201B1 (ko) 2025-06-23
IL305193A (en) 2023-10-01
CN113105552A (zh) 2021-07-13
CN113105551B (zh) 2024-10-25
CN113105551A (zh) 2021-07-13
FI3237005T3 (fi) 2024-12-02
ES2995733T3 (en) 2025-02-11
HRP20241502T1 (hr) 2025-01-03
CN113150165B (zh) 2024-09-03
CN113512121A (zh) 2021-10-19
RS66070B1 (sr) 2024-11-29
EP4491195A3 (en) 2025-04-02
ES2962675T3 (es) 2024-03-20
KR102590385B1 (ko) 2023-10-18
US20170073418A1 (en) 2017-03-16
WO2016106158A1 (en) 2016-06-30
CN113512122B (zh) 2024-09-10
CN106659779B (zh) 2021-05-18
CN113512120A (zh) 2021-10-19
US20170369587A1 (en) 2017-12-28
CN113512120B (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
NZ728749A (en) Anti-pd-l1 antibodies
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
NZ745357A (en) Antigen binding proteins that bind pd-l1
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
MX2016003593A (es) Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
MX2015012540A (es) Ratón de cadena ligera común.
AU2014232501C1 (en) Heterodimeric proteins
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX388181B (es) Anticuerpos anti-pd-1.
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
HK1205873A1 (en) Common light chain mouse
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
HK1208994A1 (en) Methods for making fully human bispecific antibodies using a common light chain
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
AR105267A1 (es) Anticuerpos de unión a tau
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
HK1231497A1 (zh) 表现不同结合特徵的vl抗原结合蛋白
LT3265487T (lt) Modifikuoti igg antikūnai, kurie su dideliu afiniškumu, avidiškumu ir specifiškumu rišasi su transformuojančiu augimo faktoriumi-beta1

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SYSTIMMUNE, INC., US

Effective date: 20190403

Owner name: SICHUAN BAILI PHARMACEUTICAL CO., LTD., CN

Effective date: 20190403

ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3569991, GAO, ZEREN, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569992, TAN, PHIL, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569993, KOVACEVICH, BRIAN, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569994, RENSHAW, BLAIR, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569995, ADAMO, JEFFREY, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569996, MAK, NGA SZE AMANDA, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569997, ZHUO, SHI, ZHONGHAIJINCHENG, NO.8, JINLV ROAD, WUHOU AVENUE, WUHOU DISTRICTCHENGDU, SICHUAN, CN; 3569998, CHEN, LAN, YOUKELIANBANG III, NO.1, DONGJIAWAN NORTH ROAD, WUHOU DISTRICTCHENGDU, SICHUAN, CN; 365477

Effective date: 20190408

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2020 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20190919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2021 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20201218

ASS Change of ownership

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD., CN

Effective date: 20211029

Owner name: SYSTIMMUNE, INC., US

Effective date: 20211029

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2022 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20211105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2023 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20220919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2024 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20230919

ASS Change of ownership

Owner name: SYSTIMMUNE, INC., US

Effective date: 20240510

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251106